We Think Jinxin Fertility Group (HKG:1951) Can Stay On Top Of Its Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like

Simply Wall St20:29 ET

The main product A400 (EP0031) of Colombotai Bio-B (06990.HK) was approved by the US Food and Drug Administration to begin phase 2 testing

Gelonghui, May 3 | Columbotai Bio-B (06990.HK) announced that the company's main product, A400 (EP0031) (rearrangement during transfection (RET) small molecule kinase inhibitor project, also known as KL590586 or EP0031), was approved by the US Food and Drug Administration (FDA) to enter phase 2 clinical development. A400 (EP0031) is a second-generation selective RET inhibitor (SRI) and has broad activity against common RET gene fusions and mutations. In March 2021, the company became an international drug development company headquartered in the United Kingdom

Gelonghui FinanceMay 3 10:25 ET

Chuangsheng Group-B (06628.HK) spent HK$91,000 to buy back 50,000 shares on May 3

Gelonghui May 3 | Chuangsheng Group-B (06628.HK) announced that it spent HK$91,000 to repurchase 50,000 shares on May 3.

Gelonghui FinanceMay 3 09:26 ET

Hong Kong stocks closed (05.03) | Hang Seng Index closed up 1.48%, Technet stocks and gaming stocks once again strong, Fast Dog Taxi (02246) surged 1.25 times during the intraday period

Overnight, the Nasdaq China Golden Dragon Index surged 6%, driving today's technology stocks collectively higher. The Hengke Index once reached the 4,000 mark in early trading; the Hang Seng Index recorded “nine consecutive gains”, setting a record for the longest continuous rise since 2018.

Zhitong FinanceMay 3 04:39 ET

[Broker Focus] CMB International Pharmaceutical Cutting Kangde (02359) has a target price of 20.9%, which indicates that its first-quarter results were stable in a difficult environment

Jinwu Financial News | According to CMB International Development Research Report, Yao Ming Kangde (02359/603259)'s 1Q performance was stable in a difficult environment. Revenue fell 11.0% year on year to 7.98 billion yuan. Excluding COVID-19 commercialization projects, revenue fell 1.8% year on year, and adjusted non-IFRS net profit fell 18.3% year on year to 1.91 billion yuan. Management maintains the 2024 performance guidelines. Revenue is expected to reach 383 to 40.5 billion yuan. Excluding COVID-19 commercialization projects, it will increase by 2.7 to 8.6%. At the same time, the non-IFRS net interest rate is expected to remain comparable to 2023

金吾財訊May 3 02:08 ET

Changes in Hong Kong stocks | CRO concept stocks fell across the board, Yakming Kangde (02359) fell more than 7%, leading the decline, and the company's profit margin for the first quarter fell short of expectations

CRO concept stocks fell across the board. As of press release, Yao Ming Kangde (02359) fell 6.47% to 36.15 yuan; Gloria Ying (06821) fell 5.33% to 63.05 yuan; Kanglong Chemical (03759) fell 4.96% to HK$9.96.

Zhitong FinanceMay 2 23:26 ET